老年患者三种血浆代谢物可区分轻度认知障碍和阿尔茨海默病：一项初步研究。
Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study.
机构信息
Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, Rua Dr. Ovídio Pires de Campos, 785, 3º andar, Sao Paulo, 05403-010, Brazil.
Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Conselho Nacional de Desenvolvimento Cientifico e Tecnológico, Sao Paulo, Brazil.
出版信息
Eur Arch Psychiatry Clin Neurosci. 2020 Jun;270(4):483-488. doi: 10.1007/s00406-019-01034-9. Epub 2019 Jun 19.
The metabolomic profile of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) may suggest potential diagnostic biomarkers and provide information on the pathophysiology of dementia. Our aim was to quantify plasmatic metabolites of AD patients, MCI and controls. We investigated the metabolomic profile-using the AbsoluteIDQ®p180 assay-of 79 older adults with primary cognitive impairment (34 AD and 20 MCI) and 25 healthy elders (controls). A cluster analysis revealed that a combination C12-DC, C12 and PCaaC26:0 could differentiate the patients according to diagnostic. Future studies should combine metabolomic profiles with other biomarkers to identify diagnostic groups.
阿尔茨海默病（AD）和轻度认知障碍（MCI）患者的代谢组学特征可能提示潜在的诊断生物标志物，并提供痴呆病理生理学的相关信息。本研究旨在定量分析 AD 患者、MCI 患者和对照组的血浆代谢物。我们使用 AbsoluteIDQ®p180 检测法分析了 79 名患有原发性认知障碍的老年人（34 名 AD 患者、20 名 MCI 患者）和 25 名健康老年人（对照组）的代谢组学特征。聚类分析显示，C12-DC、C12 和 PCaaC26:0 的组合可以根据诊断结果区分患者。未来的研究应将代谢组学特征与其他生物标志物相结合，以识别诊断组。
Zotero 插件